- February’s Look Good Feel Better workshop a great success
- Cancer research from the University of Windsor has sparked call for action by global health organization
- Scientists discover new molecule that protects heart from breast cancer drug toxicity
February’s Look Good Feel Better workshop a great success Our monthly Look Good Feel Better workshop has been a popular fixture at Cancerkin and this month’s session proved to be no different. Eleven of our patients attended LGFB commenting on how positive and uplifting the experience was, with one attendee saying “It was very supportive and very good advice was given. Well done and thank you”. Cancerkin would like to say a big thank you to Look Good Feel Better for all their support and to their volunteers for their enthusiasm and energy that helped to make this workshop so engaging.
If you would like to book onto a Look Good Feel Better workshop, please contact Reema on email@example.com or call 0207 830 2323. Please note Look Good Feel Better sessions are only available to those who have not attended a previous workshop.
Cancer research from the University of Windsor has sparked call for action by global health organization Occupational health researchers at the University of Windsor, Canada, Jim Brophy and Margaret Keith, have pioneered “ground-breaking” research into the possible risks of breast cancer in the workplace which has ‘sparked a call for global action’ by the American Public Health Association (APHA).
As part of a wider research team, which involved the collaboration of Canadian, Northern Ireland and US institutes, Brophy and Keith collated the occupational histories of more than 1000 women being treated for breast cancer and a matching number of women who had not developed the disease; serving as a control group. Findings showed women working in “high-risk” jobs such as automotive plastics, farming and metal industries were shown to have higher incidences of breast cancer – and certain types of occupations posed a greater risk compared to other notable risk factors such as poor diet and exercise.
“Breast cancer is the most prevalent cancer among women in North America, but the majority of women do not have the known or suspected risk factors. More attention to the exposures and hazards faced by women at work is urgently required” said Brophy. Keith added, “This lack of gender perspective comes at a heavy price to many working women”.
One significant implication that these results will have for cancer prevention is the finding that women who work in food canning and automotive plastics have a risk of developing pre-menopausal breast cancer five times greater than those who work in other industries.
In light of this research, APHA has passed a resolution that will involve the organisation lobbying and pushing industry, lawmakers and decision-makers to ensure safeguards to limit employee exposure to suspected occupational carcinogens. APHA committee co-chair, Celeste Monforton, has described this study as “landmark work” with the hope that it will generate international attention and bring about more focus for working women and cancer.
Scientists discover new molecule that protects heart from breast cancer drug toxicity Dr Alessandra Ghigo, who led ground-breaking research into a new molecule that could help protect the heart from toxicity caused by anti-cancer therapy, explained the importance of research into the new medical field of cardio-oncology, “Cardiotoxicity of cancer drugs has become an increasing problem in the last decade due to the increasing success of anticancer therapy and aggressive use of these drugs. More people are now surviving cancer but it is estimated that 32% of them could die of heart disease caused by their treatment”.
The study explored a potential solution to the cardiotoxic side effects of cancer drugs by focussing on the role of an enzyme key to heart regulation called PI3K. When a molecule which inhibited PI3K activity was used it not only helped to protect heart function in mice but also aided the activity of doxorubicin, a chemotherapy drug used to treat many different forms of cancer, by working with it synergistically to slow tumour growth.
These findings could have positive wider implications for chemotherapy as Dr Ghigo explains: “One of the main problems with the cardiotoxicity induced by chemotherapy is that the anticancer regimens need to be modified. We may have to use lower doses of agents to prevent the cardiotoxicity or stop the treatment. By using this inhibitor of PI3K, together with the chemotherapy, we could allow a wider and safer use of anticancer therapies because we don’t need to lower the dose or change the treatment.”